Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

NCT00558272 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Prostate Cancer
Bone Neoplasms

Interventions

DRUG: AZD0530
DRUG: Zoledronic Acid

Sponsor

AstraZeneca